

Тіро	Periódico
Título	The hindrances to perform the COVID-19 vaccination in Brazil
Autores	BOSCHIERO, MATHEUS NEGRI; PALAMIM, CAMILA VANTINI CAPASSO; MARSON, FERNANDO AUGUSTO LIMA
Autor (es) USF	BOSCHIERO, MATHEUS NEGRI; PALAMIM, CAMILA VANTINI CAPASSO; MARSON, FERNANDO AUGUSTO LIMA
Autores Internacionais	
Programa/Curso (s)	Programa de Pós-Graduação Stricto Sensu em Ciências da Saúde
DOI	doi: 10.1080/21645515.2021.1955607
Assunto (palavras chaves)	Keywords: COVID-19; SARS-CoV-2; immunization; public health; vaccine; viral infection
Idioma	Inglês
Fonte	Título do periódico: Human Vaccines & Immunotherapeutics. ISSN: 2164-5515; 2164-554X Volume/Número/Paginação/Ano: 17/11/3989-4004/2021
Data da publicação	2021 Nov 2
Formato da produção	Impressa ou digital
Resumo	Introduction: Brazil is one of the epicenters of COVID-19 pandemic and faces several hindrances to make his COVID-19 vaccination plan efficient. Methods: The Brazilian COVID-19 vaccination plan was evaluated and the hindrances to make the COVID-19 vaccination plan efficient were described and discussed. Results: High territorial extension might contribute to a delay on the COVID-19 vaccination, due to difficulty in delivering vaccines to furthest Brazilian states and to all the interior cities. The choice among the vaccines should be done based on the type of storage and must consider the transport conditions necessary to maintain its effectiveness. The indigenous individuals were included with health-care workers as the first group to be vaccinated, inflaming the number of vaccines doses distributed in states where the indigenous population have higher prevalence. The antivaccine movement and the politicization of the vaccine are also hindrances to be overcome in Brazil. The COVID-19 incidence or mortality rate and the distribution of intensive care units (ICUs) are not a criterion to distribute the vaccines, as we did not identify a correlation between these markers and the number of COVID-19 vaccines and the number of COVID-19 cases, deaths by COVID-19, gross domestic product, as well as populational density. A total of 83,280,475 doses of COVID-19 vaccines were distributed in Brazil. In the first dose, the Coronavac (Sinovac TM), AZD1222 (AstraZeneca/Oxford TM), and BNT162b (Pfizer/BioNTech TM) vaccines were responsible to vaccinate, respectively, 9.61%, 6.69%, and 0.35% of the Brazilian population. In the second dose, the Coronavac, AZD1222, and BNT162b vaccines were responsible to vaccinate, respectively, 7.52%, 0.53%, and <0.01% of the Brazilian population.





	Conclusions: The Federal Government must evaluate the hindrances and propose
	solutions to maximize the immunization against COVID-19 on Brazil.
Fomento	

